Recombinant Factor VIII Fc Fusion Protein for First-time Immune Tolerance Induction: Final Results of the verITI-8 Study

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Recombinant Factor VIII Fc Fusion Protein for First-time Immune Tolerance Induction: Final Results of the verITI-8 Study

header-info

Apr, 27, 2023

verITI-8 is the first prospective study of first-time rFVIIIFc ITI for severe hemophilia A and high historical peak titers. As the first extended half-life rFVIII with prospective data in ITI, rFVIIIFc offered short time to tolerization with durable responses in almost two-thirds of patients and was well tolerated.

Access the full article to read more here.